Post Carotid Stenting Cerebral Hyperperfusion: a Preventable Complication

This syndrome, which can be reverted, is also one of the causes of preventable stroke, at least in the context of carotid endarterectomy. At present, there is little information on the incidence of this condition in the context of carotid stenting, which is the purpose of this study, in addition to providing tips to prevent it.

Síndrome de Hiperperfusión cerebral post-angioplastia carotídea: una complicación prevenibleA systematic search resulted in 33 studies with a total 8731 carotid stenting procedures reporting 4.6% hyperperfusion risk (3.1 to 6.8%). Nearly half of hyperperfusion patients later had a stroke (47%), and more than half of strokes resulted fatal or disabling (54%).

 

Symptoms did not appear immediately after procedure, but at average 12 hours after procedure (8 to 36 hour range). This is clearly different form embolic stroke, also diagnosed in the same cath lab.


Read also: Far from a Being a Pun, Malnutrition Tips the Scales in TAVR.


Impaired cerebrovascular reserve was associated to higher risk of post stenting hyperperfusion syndrome (RR 5.18; CI 95% 1.0 to 26.8; p=0.049).

 

If the procedure takes place in the context of a symptomatic patient, the risk of periprocedural stroke is a lot higher ─this we have known for some time now. What we did not know is that evolution with hyperperfusion syndrome involves significantly lower risk of stroke compared to acute patients (RR 0.20; IC 95% 0.07 to 0.59; p=0.001).


Read also: Cost-Effectiveness of Frenestrated or Branched Endoprostheses vs. Open Surgery.


Patients with bilateral carotid stenosis or very critical lesions should be watched closely in the first hours after procedure, and their blood pressure needs to be monitored obsessively.

 

Conclusion

Cerebral hyperperfusion syndrome is relatively frequent and serious in patients undergoing carotid stenting, and it appears in the first hours after procedure, never immediately. We should encourage further research to find out how to treat this phenomenon, and also how to control blood pressure and measure cerebral blood flow.

 

Original title: Cerebral Hyperperfusion Syndrome After Carotid Artery Stenting: A Systematic Review and Meta-analysis.

Reference: Anne E. Huibers et al. Eur J Vasc Endovasc Surg (2018). Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...